J Clin Oncol: Rituximab + Lenalidomide + Ibrutinib in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) has remained largely unchanged for decade.

The study was designed to evaluate the efficacy and safety of the combination of rituximab, lenalidomide, and ibrutinib in newly diagnosed diffuse large B-cell lymphom.

This is an investigator-initiated, single-arm, Phase 2 clinical trial that enrolled 60 patients with newly diagnosed non-germinal center B-cell-like DLBCL to receive rituximab (375 mg/m2, day 1) , lenalidomide (25 mg/day, days 1-10) and ibrutinib (560 mg/day) (RLI) were treated sequentially, with 21 days as a course of treatmen.

The median age of patients tested was 65 years (range, 29-83 years), and 28% of patients were 70 years or olde.

It is understood that this study is the first clinical study of targeted therapy for newly diagnosed DLBCL before chemotherap.

Original source:

Jason Westin, et a.